Publications by authors named "Konstantinos Mathioudakis"
Increased prevalence of inflammatory arthritis, systemic lupus erythematosus and systemic sclerosis, during 2020-2023 versus 2016-2019 in a Nation-Wide Cohort Study.
Rheumatol Int
December 2024
Article Synopsis
- A study in Greece looked at how common autoimmune rheumatic diseases (ARD) are over time, comparing the years 2016-2019 to 2020-2023, including the effects of the Covid-19 pandemic.* ! -
- The results showed that diseases like Rheumatoid Arthritis and Psoriatic Arthritis became more common during the pandemic period, especially among younger and older adults.* ! -
- There was a big increase in the number of people with these diseases, so Greece will need more resources like doctors and medicine to help all these patients.* !
Background: Drug persistence is a crucial aspect of treatment success in psoriasis.
Objectives: To record real-world evidence concerning drug survival of biologic agents used for psoriasis treatment and to detect associated modifying factors in Greece.
Methods: This was a retrospective cohort study based on data extracted from the nationwide Greek prescription system.
Real-world data on treatment patterns in at least high cardiovascular risk patients on dual and triple lipid lowering therapy in a Hellenic nationwide e-prescription database.
Int J Cardiol Cardiovasc Risk Prev
June 2024
Background: Despite recent guidelines appropriate lipid-lowering treatment (LLT) remains suboptimal in everyday clinical practice.
Aims: We aimed to describe clinical practice of use of LLT for at least high CV risk populations in a Hellenic real-world setting and assess how this relates to the European Society of Cardiology treatment guidelines.
Methods: We analyzed data from a retrospective cohort study of the National Registry of patients with dyslipidemia between 1/7/2017 and 30/6/2019 who were at least of high CV risk and filled a dual or triple lipid-lowering treatment (dLLT, tLLT) prescription.
Objectives: Patients with RA were at increased risk for COVID-19-associated hospitalization and death during the first year of the pandemic in Greece. We aimed to examine their outcomes after the SARS-Cov-2 Omicron, a more contagious but with milder clinical impacts variant, prevailed.
Methods: A retrospective, nationwide study was conducted between 1 January 2022 and 30 June 2022 in all RA patients under treatment and matched (1:5) on age, sex and region of domicile random general population comparators.
Article Synopsis
- The study aimed to understand the increased risks of hospitalization and death due to COVID-19 in patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA), systemic lupus erythematosus (SLE), and systemic sclerosis (SSc) compared to the general population during the pandemic's first year.
- Researchers analyzed data from nationwide electronic registries, tracking COVID-19 cases, hospitalizations, deaths, and all-cause mortality in nearly 75,000 treated patients and a matched group from the general population.
- Findings revealed that patients with RA, SLE, and SSc faced significantly higher rates of COVID-19 hospitalization and deaths, particularly in RA and
Article Synopsis
- In Greece, only 42% of the estimated 683,679 osteoporotic individuals were receiving anti-osteoporotic treatment in 2019, highlighting a treatment gap especially pronounced in males.
- The study utilized a comprehensive prescription database covering nearly the entire Greek population, identifying that only 3.3% of adults had filled at least one anti-osteoporotic prescription, with the prevalence increasing significantly with age.
- The most commonly prescribed medications were oral bisphosphonates (58.8%) and denosumab (39.4%), and the average annual treatment cost per patient varied with age, reaching approximately €32.
Article Synopsis
- The study aimed to compare all-cause mortality rates in patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA), systemic lupus erythematosus (SLE), and systemic sclerosis (SSc) against the general population.
- It analyzed anonymized data from over 11 million Greek citizens and found that survival rates were the lowest for SSc, followed by SLE and inflammatory arthritis, with increased mortality observed over time.
- Despite improvements in survival for RA, AS, and PsA, patients with SLE and SSc had significantly higher mortality rates, especially among men and those under 50 years old.
Introduction and switching of biologic agents are associated with antidepressant and anxiolytic medication use: data on 42 815 real-world patients with inflammatory rheumatic disease.
RMD Open
September 2020
Objectives: Depression and anxiety are linked bi-directionally with inflammatory rheumatic diseases (IRDs) activity, which in turn, depends on subjective patient reported outcomes that can be distorted by comorbid mood disorders. We tested the hypothesis that introduction and/or switching of biologic agents for IRDs are associated with treatment for depression and/or anxiety, by analysing real-world data.
Methods: Using a country-wide electronic prescription database (10 012 604 registered, 99% population coverage), we captured almost all patients with rheumatoid arthritis (n=12 002), psoriatic arthritis (n=5465) and ankylosing spondylitis (n=6423) who received biologic disease modifying anti-rheumatic drugs (bDMARDs) during a 2-year period (8/2016-7/2018).